Time to show efficacy of venetoclax

Venetoclax (Venetoclax ) is an innovative leukemia treatment drug. The time for its efficacy to appear is not fixed, but is affected by many factors. This includes individual patient differences, the type of leukemia, the severity of the condition and whether it is used in combination with other drugs.

For people with chronic lymphocytic leukemia (CLL), venetoclax usually starts to work within the first few weeks of treatment. Clinical studies have shown that patients may observe a significant reduction in the number of leukemia cells within 4 to 8 weeks before treatment. When venetoclax is combined with drugs such as obinutuzumab (Obinutuzumab), its efficacy may be more significant. However, to ensure patient safety and reduce side effects, the dose of venetoclax needs to be titrated gradually, usually reaching the maximum dose within 5 weeks.

For patients with acute myeloid leukemia (AML), especially those who are elderly or unable to tolerate intensive chemotherapy, venetoclax is often used in combination with other low-dose chemotherapy drugs such as azacitidine (Azacitidine) or decitabine (Decitabine). In this case, some benefit can also be observed within the first few weeks of treatment. But it usually takes 4 to 6 weeks of treatment to more accurately assess a patient's response to the drug. For acute leukemias such as AML, venetoclax may be able to quickly reduce the level of leukemia cells in the blood, but the long-term efficacy still needs to be further verified through maintenance treatment for several months or even longer.

In summary, the time for the efficacy of venetoclax to appear varies from patient to patient and is affected by multiple factors. The doctor will develop a personalized treatment plan for the patient based on the patient's specific situation, treatment plan and efficacy evaluation results, and adjust treatment measures in a timely manner to ensure the best treatment effect.